Verona Pharma Plc is a London-based biopharmaceutical company focused on creating treatments for respiratory diseases lacking adequate therapies. Its leading product, ensifentrine, is a novel compound with dual action as a bronchodilator and anti-inflammatory agent, currently in Phase 3 trials for conditions like chronic obstructive pulmonary disease, asthma, and cystic fibrosis. Verona Pharma is exploring ensifentrine in various forms, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, aiming to meet critical healthcare needs.